By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Synthetic Genomics and Integrated DNA Technologies today announced a deal to manufacture, market, and commercialize small synthetic gene products.

The deal, the terms of which were not disclosed, calls for the companies to construct custom, synthetic, double-stranded nucleic acids up to 5 kilobases. IDT will combine its expertise in custom oligonucleotide manufacturing with Synthetic Genomics' technology to assemble small gene constructs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.